首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients.
【24h】

Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients.

机译:肺移植受者中ADAMTS 13活性获得性缺乏的血栓性微血管病。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Thrombotic microangiopathy may develop after solid organ transplantation, but it is usually not associated with severe deficiency in von Willebrand factor-cleaving metalloprotease (ADAMTS 13) activity. METHODS: We present the cases of two lung transplant recipients who experienced a thrombotic microangiopathy associated with an acquired severe (<5%) deficiency in ADAMTS 13 activity. RESULTS: A major feature of both cases was the occurrence of a diffuse alveolar hemorrhage. CONCLUSION: Our two cases of lung transplant patients, with thrombotic microangiopathy related to an acquired ADAMTS 13 deficiency recipients, confirm that this mechanism may also be involved in the pathogenesis of thrombotic microangiopathy developing after solid organ transplantation. Therefore, we consider that ADAMTS 13 activity should be assessed on a systematic basis in this setting.
机译:背景:实体器官移植后可能会形成血栓性微血管病,但通常与von Willebrand因子裂解金属蛋白酶(ADAMTS 13)活性的严重缺陷无关。方法:我们介绍了两名肺移植受者的案例,这些接受者经历了血栓性微血管病变,并伴有ADAMTS 13活性获得性严重(<5%)缺陷。结果:这两个病例的主要特征是发生弥漫性肺泡出血。结论:我们的两例肺移植患者血栓性微血管病与获得性ADAMTS 13缺乏受体有关,证实该机制也可能与实体器官移植后血栓性微血管病的发病机理有关。因此,我们认为在这种情况下应系统地评估ADAMTS 13的活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号